At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), a highlight came during the President's Choice Lecture, where former NIH director Francis ...

A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving ...

VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of Velacur TM – the first handheld 3D liver health ...

Please provide your email address to receive an email when new articles are posted on . The AASLD and IDSA HCV Guidance Panel has released updated guidelines for the treatment of hepatitis C virus ...

Editor's Note: Choosing Wisely®, an initiative of the American Board of Internal Medicine (ABIM) Foundation, comprises evidence-based recommendations from specialty organizations on commonly used ...

The American Association for the Study of Liver Diseases, along with other societies, has updated guidelines for the treatment of hepatitis C viral infection (HCV), including the use of direct-acting ...

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- At the meeting, one poster presentation ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...

Please provide your email address to receive an email when new articles are posted on . The AASLD released a practice guidance document for the diagnosis and management of nonalcoholic fatty liver ...

DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics showcased new data yesterday at the American Association for the Study of Liver Diseases (AASLD) conference ...

Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET “Through our core ...